Portal de investigación
Recent evidence in epigenomics and proteomics biomarkers for early and minimally invasive diagnosis of Alzheimer's and Parkinson's diseases.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Mayo, Sonia
- Benito-Leon, Julian
Grupos
Abstract
Alzheimer's (AD) and Parkinson's diseases (PD) show deposits of improperly folded modified proteins, so protein expression mechanisms are involved since early stages. Several studies evaluated epigenomics and proteomics profiles in these patients, with promising results. In general, they focused on early, specific, and minimally invasive biomarkers for diagnosis and prognosis of AD and PD.
Datos de la publicación
- ISSN/ISSNe:
- 1570-159X, 1875-6190
- Tipo:
- Review
- Páginas:
- 1273-1303
- PubMed:
- 33357195
- Factor de Impacto:
- 1,955 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Current Neuropharmacology BENTHAM SCIENCE PUBL LTD
Citas Recibidas en Web of Science: 43
Documentos
- No hay documentos
Filiaciones
Keywords
- Alzheimer’ s disease, Parkinson’ s disease, biomarkers, diagnosis, early, epigenomics, proteomics
Campos de Estudio
Cita
Mayo S,Benito J,Pena C,Baquero M,Cháfer C. Recent evidence in epigenomics and proteomics biomarkers for early and minimally invasive diagnosis of Alzheimer's and Parkinson's diseases. Curr. Neuropharmacol. 2020. 19(8):p. 1273-1303. IF:7,390. (1).